The short version of Anti-doping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-18 and is reviewed periodically as new material appears.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
== Bibliography == Guillén, Mauro F.; García-Cana, Esteban (2010). Guillén, Mauro F.; García-Cana, Esteban (2010). The New Multinationals: Spanish Firms in a Global Context (in Spanish). Cambridge: Cambridge University Press. ISBN 9780521516143. VV.AA. (2012). Expansión (ed.). Las 40 empresas que crecen en tiempos de crisis (in Spanish). Bubok Publishing. ISBN 978-84-686-3028-1. Martínez Bernal, Pablo; Freischütz, Christian (2026). Los outsiders ibéricos. Ocho equipos directivos y el secreto de su éxito (in Spanish). Madrid: Marcial Pons. ISBN 9791399097016.
Stoess, on the other hand, had reestablished relations with Eastman Kodak in the United States and was bringing large quantities of much-needed foreign exchange to Germany. After World War II, Paul Koepff Jr. became managing director of the Stoess company in Eberbach. In 1949, he built up a gelatin capsule factory there. In the course of the decades, DGF AG bought various factories worldwide. In 1965, it was taken over by the "Chem. Werke Stoess" in Heidelberg. In that year Heinrich Koepff took over the majority of shares of the Göppingen plant and through his marriage to the granddaughter of the company founder, Gerda Stoess, the companies merged. In 1972, the association traded under the name DGF Stoess & Co. GmbH. In 1989, the company was converted into a public limited company. The gelatin production division was renamed the Gelita Group in 1999. In 2005, all entities started to sell gelatine under the brand name Gelita.
Deficient scar formation: Results in wound dehiscence or rupture of the wound due to inadequate formation of granulation tissue. Excessive scar formation: Hypertrophic scar, keloid, desmoid. Exuberant granulation (proud flesh). Deficient contraction (in skin grafts) or excessive contraction (in burns). Pigmentary changes such as Postinflammatory hyperpigmentation Others: Dystrophic calcification, painful scars, incisional hernia Other complications can include infection and Marjolin's ulcer.
Sources: en.wikipedia.org
=== Comprehensive Drug Abuse and Control Act === The original act, passed in 1970, allowed governments to attain funds, drugs, and equipment seized during raids through civil court hearings and drug convictions. Over the years, the list of items allowed to be seized grew in size. In 1984, the Act was amended to allow federal law enforcement agencies to "retain and use any and all proceeds from asset forfeitures, and to allow state and local police agencies to retain up to 80 percent of the assets value." The law now allowed police units to seize cars, cash, and property from drug raids, even without a conviction. "Because those who were targeted were typically poor or of moderate means, they often lacked resources to hire an attorney or pay the considerable court costs. As a result, most people who had their property seized did not challenge the government's action, especially because the government could retaliate by filing criminal charges." Between 1989 and 1992, federally funded state and local police agencies seized over $1 billion in assets. That did not include the DEA or other federally funded enforcement agencies.
Drew's first appointment as a faculty instructor was for pathology at Howard University from 1935 to 1936. He then joined Freedman's Hospital, a federally operated facility associated with Howard University, as an instructor in surgery and an assistant surgeon. In 1938, Drew began graduate work at Columbia University in New York City on the award of a two-year Rockefeller Fellowship in surgery. He then began postgraduate work, earning his Doctor of Science in Surgery at Columbia University. He spent time doing research at Columbia's Presbyterian Hospital and wrote a doctoral thesis, Banked Blood: A Study on Blood Preservation, based on an exhaustive study of blood preservation techniques. It was through this blood preservation research that Drew realized blood plasma was able to be preserved two months longer through de-liquification, or the separation of liquid blood from the cells. When ready for use the plasma would then be able to return to its original state via reconstitution. This thesis earned him his Doctor of Science in Medicine degree in 1940, becoming the first African American to receive one. The District of Columbia chapter of the American Medical Association allowed only white doctors to join, so "Drew died without ever being accepted for membership in the AMA."
A homotetramer is a protein complex made up of four identical subunits which are associated but not covalently bound. Conversely, a heterotetramer is a 4-subunit complex where one or more subunits differ. Examples of homotetramers include:
Chymotrypsins (EC 3.4.21.1, including enzymes called alpha-chymotrypsin, chymotrypsin A, and chymotrypsin B) are digestive enzymes that form a component of pancreatic juice acting in the duodenum, where they perform proteolysis, the breakdown of proteins and polypeptides. In humans, the corresponding enzymes are encoded by the genes CTRB1 and CTRB2. The related enzyme chymotrypsin-C (EC 3.4.21.2) acts similarly, but with some differences including a preference for cutting leucine over phenylalanine bonds. Chymotrypsin preferentially cleaves peptide amide bonds where the side chain of the amino acid N-terminal to the scissile amide bond (the P1 position) is a large hydrophobic amino acid (tyrosine, tryptophan, and phenylalanine). These amino acids contain an aromatic ring in their side chain that fits into a hydrophobic pocket (the S1 position) of the enzyme. It is activated in the presence of trypsin. The hydrophobic and shape complementarity between the peptide substrate P1 side chain and the enzyme S1 binding cavity accounts for the substrate specificity of this enzyme. Chymotrypsin also hydrolyzes other amide bonds in peptides at slower rates, particularly those containing leucine at the P1 position. Structurally, it is the archetypal structure for its superfamily, the PA clan of proteases.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.